GlyNAC supplementation for 24 weeks lowered IL‐6, TNFα, hsCRP by 77, 57% and 49%; increased IL‐10 by 38%; decreased sICAM1, sVCAM1 and E‐selectin by 60%, 46% and 35%; significantly lowered fasting plasma glucose (9% lower), insulin (55% lower) and insulin resistance (59% lower); and lowered 8OHdG by 66%. This evidence concerns the gene IL6 and Insulin resistance.